Theravance Biopharma Inc

The Multiple System Atrophy (MSA) Market is projected to grow from US$ 148.1 Million in 2024 to US$ 202.3 Million by 2031, at a CAGR of 4.5%. This growth is driven by the rising prevalence of MSA, increasing R&D activities, and advancements in diagnostic techniques. Key players include Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., and Sumitomo Dainippon Pharma Co., Ltd.